Overview Recently Resected Patient Extending Adjuvant GLIVEC Recurrence Post Adjuvant Therapy Metastatic Patient With Progression After GI/Surgeon Diagnosis About GIST
Print
Font size:

KIT+ GIST : Recently Resected Patient

Recently Resected Patient/GLIVEC and KIT+ GIST
1,2
61 years old
3 months since diagnosis
Gastric KIT+ GIST Original tumor: 3 cm
Mitotic rate: >5/50 HPFs
16% RISK OF RECURRENCE3

Successfully resected patients may be convinced they are cancer free. They need to know:

  • GIST has malignant potential, even after resection1,4
  • GLIVEC is the only approved adjuvant therapy for KIT+ GIST5,6
  • The National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) recommend at least 36 months of imatinib therapy following resection in patients with significant risk of recurrence1,7 *
  • Adjuvant therapy with GLIVEC can significantly lower the risk of tumor recurrence5,8

Make an informed decision regarding postsurgical treatment with GLIVEC

Risk of Recurrence

Adjuvant GLIVEC vs Placebo Study Design

Efficacy Data

Risks and Benefits

GIST=gastrointestinal stromal tumor.

Treatment algorithm
for KIT+ GIST

View now

Prescribing
GLIVEC

Learn more

GLIVEC Product
Characteristics

View more

GLIVEC Safety
and Tolerability

Learn more

* NCCN recommends use in intermediate-risk and high-risk KIT+ GIST patients, whereas ESMO suggests use in patients with high risk.

References

  1. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 3.2012). ©2012 National Comprehensive Cancer Network, Inc.http://www.nccn.org. Accessed November 30, 2012. To view the most recent and complete version of the guidelines, go online to www.nccn.org.
  2. Reichardt P, Blay J-Y, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10(2):221-232.
  3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
  4. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-465.
  5. Glivec® (imatinib) summary of product characteristics. West Sussex, UK: Novartis Europharm Limited; 2013.
  6. Sutent® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd; 2012.
  7. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO clinical practice guidelines of diagnosis, treatment and follow-up. Ann Oncol. 2012;23(supp7):vii49-vii55.
  8. DeMatteo RP, Ballman KV, Antonescu CR, et al; for the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.

GLIVEC and KIT+ GIST

Glivec and Ph+ CML

Glivec and Additional Indications

For Your Patients

Library and Tools